With therapeutic developers and regulators embracing the potential of RWE to accelerate and improve drug discovery and clinical timelines, AI and machine learning are playing a critical role in enabling these activities. These two sessions consider key contributions the AI community is making to realize the potential of RWE and will highlight these activities though examination of two use cases: in Drug Discovery and in Clinical Applications.
Thank you to our participants:
Session #1: Regulatory Considerations of AI in Using RWE to Accelerate Drug Discovery Discussion.
Moderator:
Paul Howard, Ph.D., Director of Public Policy, Amicus Therapeutics
Panelists:
Sean Khozin, M.D., MPH, Global Head of Data Science Innovation, Janssen R&D
Lauren Silvis, J.D., Senior Vice President of External Affairs, Tempus; former Chief of Staff for Scott Gottlieb
Esther Bleicher, J.D., MPH, Executive Director, Regulatory Policy and Counsel, Valo Health
Session #2: RWD and RWE: Industry Perspectives from the Front Lines
Moderator
Rafael Rosengarten, Ph.D., CEO, Genialis
Panelists
Adem Albayrak, VP of Technology, Life Sciences Business, Health Catalyst
Blanca Baez, SVP & Global Head Pharma & Biotech, Molecular Health
Jennifer L. Carter, M.D., MPH, JLC Precision Health Strategies
Vangelis Vergetis, Ph.D., Executive Director, Intelligencia.ai